Digital Look

Welcome to Digital Look++,
you are not logged in

Oxford Biomedica (OXB)

Pharma and Biotech

412.50p

Select chart: EPS | Dividend | Revenue

Period Ending	Period	Revenue (£m)	Pre-tax (£m)	EPS	Dividend
30-Jun-24	Interim	50.81	(35.74)	(30.88)p	n/a

Year Ending	Revenue (£m)	Pre-tax (£m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
31-Dec-19	64.06	(20.89)	(22.10)p	n/a	n/a	n/a	n/a	0.0%
31-Dec-20	87.73	(6.57)	(7.81)p	n/a	n/a	n/a	n/a	0.0%
31-Dec-21	142.80	19.88	22.77p	54.0	n/a	n/a	n/a	0.0%
31-Dec-22	139.99	(45.98)	(41.29)p	n/a	n/a	n/a	n/a	0.0%
31-Dec-23	89.54	(188.53)	(163.11)p	n/a	n/a	n/a	n/a	0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Year Ending	Revenue (£m)	Pre-tax (£m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
31-Dec-24	129.82	(41.34)	(41.08)p	n/a	n/a	n/a	n/a	0.0%
31-Dec-25	167.18	(18.44)	(25.85)p	n/a	n/a	n/a	n/a	0.0%
31-Dec-26	211.33	6.16	(9.62)p	n/a	n/a	n/a	n/a	0.0%

	5 Yr High	5 Yr Low	5 Yr Avg	Curr / Avg
Latest	54.02	n/a	n/a	0

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

Find out about IFRS and how this affects the financial infomation for all UK companies.